Synarc founders played a leading role in the development of DXA and QCT techniques and their application in clinical trials.

We were also instrumental in standardizing quality-control programs for osteoporosis clinical trials and epidemiological studies, and developing many of the pivotal biochemical markers now used in evaluating bone disease. Call on us for unparalleled imaging and biochemical-marker expertise in your next osteoporosis trial.

Exceptional study site selection and subject recruitment

Synarc qualifies and selects study sites worldwide, ensuring adherence to imaging parameters and quality standards, as well as equipment accuracy. To enrich clinical trials with patients appropriate for the trial end points, Synarc also specializes in rapid and targeted subject recruitment using localized recruiting techniques and procedures.

Optimal image acquisition

Synarc provides centralized imaging services across the full spectrum of clinical development, both for bone mineral density evaluations and for vertebral fracture assessments. Our radiologists demonstrate excellent inter- and intrareader reproducibility, and our efficient data-management systems support even the largest clinical trials.

A full range of biochemical markers

Biochemical markers of bone turnover are critical endpoints in phase II dose-ranging studies, as they allow for shorter trials with fewer subjects. Synarc can help you select the appropriate biochemical markers of bone formation and resorption for your study.

Significant regulatory experience

The quality of our data and scientific expertise has played an important role in securing regulatory approval for a large number of osteoporosis therapies.